Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients

Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors 

Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis

Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease

Sanofi invests to make France its world class center of excellence in vaccine research and production

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease

Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan